Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619526 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL2007222 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL5473681 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL255679 | 0.84 | CYP1A2 (0.71) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL255663 | 0.84 | CYP1A2 (0.71) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL255664 | 0.84 | CYP1A2 (0.71) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL20791688 | 0.83 | L3MBTL1 (0.53) | SMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL20791689 | 0.83 | L3MBTL1 (0.53) | SMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL8309864 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL14521538 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137742-A1 | COMPOUNDS AND COMPOSITIONS AS FGFR3 DEGRADERS AND USES THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| WO-2023218187-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | UNIVERSITY OF DUNDEE (GB) | 2023-11-16 | — | — | WO | disclosed |
| EP-4276097-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | University Of Dundee (GB) | 2023-11-15 | — | — | EP | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| WO-2023152666-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-17 | — | — | WO | disclosed |
| EP-4215532-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1756042-A1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756043-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| WO-2005105733-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005105732-A1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | RIPK1, RIPK4, RIPK3 | SMN1; SMN2 3889/4885LMNA 1492/4885ALDH1A1 4259/4885 |
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | OPRL1, PTGER1, OPRM1 | SMN1; SMN2 1533/4885LMNA 3070/4885ALDH1A1 1061/4885 |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | SMN1; SMN2 2672/4885LMNA 1741/4885ALDH1A1 4173/4885 |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRDT, RBX1 | SMN1; SMN2 2559/4885LMNA 3556/4885ALDH1A1 4038/4885 |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | SMN1; SMN2 3422/4885LMNA 2913/4885ALDH1A1 860/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | SMN1; SMN2 2113/4885LMNA 1887/4885ALDH1A1 2833/4885 |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PTGER1, PTGER2, PTGER3 | SMN1; SMN2 1385/4885LMNA 1919/4885ALDH1A1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.